Literature DB >> 30854960

Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.

Sho-Ichi Yamagishi1, Ami Sotokawauchi1, Takanori Matsui1.   

Abstract

Accumulating evidence has shown that the incidence of atrial fibrillation (AF) is higher in patients with diabetes, especially those with poor glycemic control or long disease duration. Nonenzymatic glycation of amino acids of proteins, lipids, and nucleic acids has progressed under normal aging process and/or diabetic condition, which could lead to the formation and accumulation of advanced glycation end products (AGEs). AGEs not only alter the tertiary structure and physiological function of macromolecules, but also evoke inflammatory and fibrotic reactions through the interaction of cell surface receptor for AGEs (RAGE), thereby being involved in aging-related disorders. In this paper, we briefly review the association of chronic hyperglycemia and type 1 diabetes with the risk of AF and then discuss the pathological role of AGE-RAGE axis in AF and its thromboembolic complications. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  AGEs; RAGE; atrial fibrillation; diabetes; oxidative stress; thromboembolism.

Mesh:

Substances:

Year:  2019        PMID: 30854960     DOI: 10.2174/1389557519666190311140737

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  4 in total

Review 1.  Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.

Authors:  Ting-Wei Lee; Ting-I Lee; Yung-Kuo Lin; Yao-Chang Chen; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Cell Mol Life Sci       Date:  2020-09-23       Impact factor: 9.261

Review 2.  Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models.

Authors:  Lander Egaña-Gorroño; Raquel López-Díez; Gautham Yepuri; Lisa S Ramirez; Sergey Reverdatto; Paul F Gugger; Alexander Shekhtman; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Front Cardiovasc Med       Date:  2020-03-10

3.  Advanced glycation end product levels were correlated with inflammation and carotid atherosclerosis in type 2 diabetes patients.

Authors:  Jie Li; Haiyan Shangguan; Xiaoqian Chen; Xiao Ye; Bin Zhong; Pen Chen; Yamei Wang; Bin Xin; Yan Bi; Dalong Zhu
Journal:  Open Life Sci       Date:  2020-06-11       Impact factor: 0.938

4.  Advanced glycation end products predict long-term outcome of catheter ablation in paroxysmal atrial fibrillation.

Authors:  Allan Bohm; Lubos Urban; Lubomira Tothova; Ljuba Bacharova; Peter Musil; Jan Kyselovic; Peter Michalek; Tomas Uher; Branislav Bezak; Peter Olejnik; Robert Hatala
Journal:  J Interv Card Electrophysiol       Date:  2021-03-10       Impact factor: 1.900

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.